These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 18392391)

  • 81. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
    Cleland JG; Nikitin N; McGowan J
    Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):9-19. PubMed ID: 15038409
    [TBL] [Abstract][Full Text] [Related]  

  • 82. [Levosimendan and dobutamine have a similar profile for potential risk for cardiac arrhythmias during 24-hour infusion in patients with acute decompensated heart failure].
    Tek M; Cavuşoğlu Y; Demirüstü C; Birdane A; Ünalır A; Görenek B; Göktekin Ö; Ata N
    Turk Kardiyol Dern Ars; 2010 Jul; 38(5):334-40. PubMed ID: 21200103
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Management of acute cardiac failure by intracoronary administration of levosimendan.
    Caimmi PP; Kapetanakis EI; Beggino C; Molinari C; Giustini G; Crosio E; Reposo G; Micalizzi E; Vacca G; Grossini E
    J Cardiovasc Pharmacol; 2011 Sep; 58(3):246-53. PubMed ID: 21654504
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Levosimendan for low cardiac output: a pediatric experience.
    Egan JR; Clarke AJ; Williams S; Cole AD; Ayer J; Jacobe S; Chard RB; Winlaw DS
    J Intensive Care Med; 2006; 21(3):183-7. PubMed ID: 16672640
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Levosimendan in heart failure after surgical repair of cardiac rupture.
    Torrado H; Ventura JL; Ruiz-Majoral A; Farrero E; Rodriguez-Castro D; Carrio ML; Miralles A
    Minerva Cardioangiol; 2009 Feb; 57(1):137-8. PubMed ID: 19202525
    [No Abstract]   [Full Text] [Related]  

  • 86. Levosimendan reduces plasma amino terminal proBNP in patients with decompensated heart failure.
    Mueller T; Gegenhuber A; Haltmayer M
    Int J Cardiol; 2005 Oct; 104(3):355-6; author reply 357-8. PubMed ID: 15950299
    [No Abstract]   [Full Text] [Related]  

  • 87. Levosimendan: a retrospective single-center case series.
    Berry WT; Hewson RW; Langrish CJ; McKenzie CA; Barrett NA
    J Crit Care; 2013 Dec; 28(6):1075-8. PubMed ID: 23998721
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).
    Moiseyev VS; Põder P; Andrejevs N; Ruda MY; Golikov AP; Lazebnik LB; Kobalava ZD; Lehtonen LA; Laine T; Nieminen MS; Lie KI;
    Eur Heart J; 2002 Sep; 23(18):1422-32. PubMed ID: 12208222
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Value of IGF-I levels in the evaluation of response to treatment with levosimendan in patients with severe heart failure.
    Işık S; Cetin M; Ciçekçioğlu H; Uçar O; Çetin ZG; Ozuğuz U; Bakır F; Berker D; Güler S
    Anadolu Kardiyol Derg; 2011 Sep; 11(6):523-9. PubMed ID: 21821501
    [TBL] [Abstract][Full Text] [Related]  

  • 90. [Levosimendan for treatment of heart failure].
    Yasumura Y
    Nihon Rinsho; 2007 May; 65 Suppl 5():169-72. PubMed ID: 17571380
    [No Abstract]   [Full Text] [Related]  

  • 91. Advances in positive inotropic therapy: levosimendan.
    Frishman WH
    Crit Care Med; 2003 Sep; 31(9):2408-9. PubMed ID: 14501979
    [No Abstract]   [Full Text] [Related]  

  • 92. Correspondence concerning the article: is levosimendan better than dobutamine in acute heart failure in patients on beta blockade treatment? What is the evidence?
    Wikström BG
    Eur J Heart Fail; 2010 Aug; 12(8):893. PubMed ID: 20675671
    [No Abstract]   [Full Text] [Related]  

  • 93. Levosimendan: The current situation and new prospects.
    Moreno N; Tavares-Silva M; Lourenço AP; Oliveira-Pinto J; Henriques-Coelho T; Leite-Moreira AF
    Rev Port Cardiol; 2014 Dec; 33(12):795-800. PubMed ID: 25459636
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Use of levosimendan, a new inodilator, for postoperative myocardial stunning in a premature neonate.
    Lechner E; Moosbauer W; Pinter M; Mair R; Tulzer G
    Pediatr Crit Care Med; 2007 Jan; 8(1):61-3. PubMed ID: 17149153
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Inotropic agents in advanced heart failure: repetita iuvant?
    De Luca L
    Int J Cardiol; 2014 Sep; 176(1):6-7. PubMed ID: 25065330
    [No Abstract]   [Full Text] [Related]  

  • 96. Levosimendan improves cardiac function and survival in rats with angiotensin II-induced hypertensive heart failure.
    Biala A; Martonen E; Kaheinen P; Levijoki J; Finckenberg P; Merasto S; Louhelainen M; Muller DN; Luft FC; Mervaala E
    Hypertens Res; 2010 Oct; 33(10):1004-11. PubMed ID: 20811386
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Clinical significance of acute neurohormonal response after levosimendan treatment.
    Giannakoulas G; Giannoglou G; Vassilikos V; Martiadou K; Kalpidis P; Parharidis G; Louridas G
    Am J Cardiol; 2006 Oct; 98(8):1123-4. PubMed ID: 17027590
    [No Abstract]   [Full Text] [Related]  

  • 98. Levosimendan and gut mucosal blood flow--not all inotropes are created equal.
    Coopersmith CM
    Crit Care Med; 2005 Jan; 33(1):246-7. PubMed ID: 15644686
    [No Abstract]   [Full Text] [Related]  

  • 99. Intracoronary infusion of levosimendan to treat postpericardiotomy heart failure.
    Caimmi PP; Grossini E; Molinari C; Vacca G; Teodori G
    Ann Thorac Surg; 2006 Nov; 82(5):e33-4. PubMed ID: 17062205
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Levosimendan: a novel agent in heart failure.
    Koumallos N; Antoniades C; Tousoulis D; Shirodaria C; Stefanadis C
    Recent Pat Cardiovasc Drug Discov; 2006 Jun; 1(2):185-91. PubMed ID: 18221085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.